Peregrine Capital Management LLC Has $11.07 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Peregrine Capital Management LLC raised its position in Haemonetics Co. (NYSE:HAE) by 1.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 141,803 shares of the medical instruments supplier’s stock after acquiring an additional 2,400 shares during the period. Peregrine Capital Management LLC owned about 0.28% of Haemonetics worth $11,072,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of HAE. Nisa Investment Advisors LLC boosted its holdings in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. KBC Group NV boosted its stake in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 712 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of Haemonetics in the 3rd quarter valued at about $204,000. CWC Advisors LLC. acquired a new stake in shares of Haemonetics in the third quarter valued at about $231,000. Finally, Versor Investments LP raised its holdings in Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 300 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

HAE has been the subject of a number of analyst reports. Barrington Research decreased their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Price Performance

NYSE:HAE opened at $62.47 on Tuesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The firm has a market cap of $3.14 billion, a price-to-earnings ratio of 24.59, a P/E/G ratio of 0.98 and a beta of 0.39. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The firm’s 50-day simple moving average is $74.18 and its 200 day simple moving average is $77.22.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, sell-side analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.